Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
wet AMD
Biotech
RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen for $34.8 million upfront.
James Waldron
Aug 19, 2025 7:18am
4DMT lays off 25% of workforce while phase 3 timeline ramps up
Jul 3, 2025 4:52am
Opthea scraps wet AMD program after eye drug loses to Lucentis
Mar 31, 2025 6:55am
Opthea's eye disease drug defeated by Eylea in phase 3
Mar 24, 2025 5:24am
4DMT restructures pipeline, extending cash runway through 2028
Jan 10, 2025 2:00pm
Outlook's eye disease drug fails to match Lucentis, sinking stock
Nov 27, 2024 8:40am
